Share on StockTwits

Analysts at Maxim Group lowered their price target on shares of Cytori Therapeutics (NASDAQ:CYTX) from $10.00 to $9.00 in a research report issued to clients and investors on Tuesday, American Banking News reports. The firm currently has a “buy” rating on the stock. Maxim Group’s price objective suggests a potential upside of 261.45% from the company’s current price.

Cytori Therapeutics (NASDAQ:CYTX) opened at 2.49 on Tuesday. Cytori Therapeutics has a 1-year low of $2.00 and a 1-year high of $3.93. The stock’s 50-day moving average is $2.4 and its 200-day moving average is $2.6. The company’s market cap is $187.9 million.

Cytori Therapeutics (NASDAQ:CYTX) last released its earnings data on Monday, May 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.14). The company had revenue of $1.03 million for the quarter, compared to the consensus estimate of $2.87 million. On average, analysts predict that Cytori Therapeutics will post $-0.43 earnings per share for the current fiscal year.

Cytori Therapeutics, Inc develops cell therapies based on autologous adipose-derived stem and regenerative cells (NASDAQ:CYTX) to treat cardiovascular disease and repair soft tissue defects.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.